First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors
Status:
COMPLETED
Trial end date:
2025-01-16
Target enrollment:
Participant gender:
Summary
This is an open, single center Phase Iclinical trial to evaluate the safety, tolerability, and preliminary efficacy of MBF-362 in patients with solid tumors.